Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-Eimeria tenella IgG2a is a monoclonal antibody of the IgG2a isotype specifically directed against antigens of *Eimeria tenella*, a protozoan parasite that causes coccidiosis in poultry. In the context of immunological research and preclinical drug development, this antibody is primarily utilized as an **isotype control**. Because its target is a non-mammalian pathogen, it does not bind to mouse or human proteins, making it an ideal negative control for evaluating the specific effects of other IgG2a-based therapeutic candidates (such as anti-IL25 antibodies). It allows researchers to account for non-specific binding or Fc-receptor-mediated biological activities in various experimental systems, including the Aldara-induced psoriasiform skin inflammation model and the IL25-mediated air pouch recruitment model.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-Eimeria tenella IgG2a.